Allogene Therapeutics, Inc. — Form 8-K Summary
Reporting date: December 5, 2020; filed December 7, 2020. The filing reports clinical and development updates under Item 8.01, not quarterly financial results.
Business Context and Reporting Period
Allogene is developing allogeneic CAR T-cell therapies. The filing presents initial Phase 1 dose-escalation results from the UNIVERSAL trial of ALLO-715, a BCMA-directed therapy for relapsed/refractory multiple myeloma, based on an October 30, 2020 data cutoff.
Key Clinical and Operating Metrics
- 35 patients enrolled; 31 evaluable for safety and 26 evaluable for efficacy.
- Patients had a median of five prior lines of therapy, and 94% were penta-exposed. Four enrolled patients became ineligible for treatment because of rapidly progressing disease.
- Median time from enrollment to treatment initiation was five days.
- At the 320 million-cell dose level, overall response rate was 60%; 40% achieved a very good partial response or better.
- Across cohorts and lymphodepletion regimens, six patients achieved a VGPR+ response; five were treated with the FCA regimen. Five of six patients assessed for minimal residual disease were MRD-negative.
- Median efficacy follow-up was 3.2 months. Six of nine responders treated at the 320 million- or 480 million-cell dose levels remained in response; the longest ongoing response was six months.
- No graft-versus-host disease or ICANS was observed. Cytokine release syndrome occurred in 14 patients, or 45%, and was Grade 1 or Grade 2.
- Grade 3 or higher infections occurred in 13 patients, or 42%, including one Grade 5 event. Serious adverse events of Grade 3 or higher occurred in 19% of patients.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial statement metrics.
Material Changes Versus the Prior Comparable Period
The filing does not present a prior-period financial or clinical comparison. It provides initial results from the UNIVERSAL trial and updates the company’s development pipeline.
Guidance, Outlook, Risks, and Unusual Items
- UNIVERSAL is continuing to enroll patients at higher ALLO-715 and ALLO-647 doses to optimize treatment.
- A combination study of ALLO-715 with SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, is expected to begin enrollment in the first half of 2021.
- An IND for ALLO-605, the company’s first TurboCAR candidate targeting BCMA, was expected to be submitted in the first half of 2021.
- The FDA cleared an IND for a Phase 1 trial of ALLO-316, a CD70-directed therapy for advanced or metastatic clear cell renal cell carcinoma; enrollment was expected to begin in 2021.
- Key risks include the early-stage nature of the data, limited patient numbers and follow-up, treatment-related infections, cytokine release syndrome, serious adverse events, progressive disease, and the reported Grade 5 event associated with progressive myeloma and the conditioning regimen.
- ALLO-715, ALLO-605, and ALLO-316 use Cellectis’ TALEN gene-editing technology under an exclusive license covering relevant allogeneic products and global development and commercial rights.
Facts Investors Should Verify
- Durability of responses and MRD-negative outcomes with longer follow-up.
- Safety results at higher doses and under different lymphodepletion regimens.
- Progress and enrollment timing for the nirogacestat combination, ALLO-605, and ALLO-316 programs.
- Future filings for cash runway, financing needs, operating expenses, and other liquidity information, which are not included in this 8-K.
- Whether early clinical findings translate into controlled-trial efficacy and regulatory approval.